Rilonacept for the treatment of recurrent pericarditis

References

• Imazio M. Treatment of recurrent pericarditis. Revista Espanola de Cardiologia (English Ed.). 2014;67(5):345–348.
   PubMed Web of Science ®Google Scholar
• Adler Y, Charron P, Imazio M, et al. ESC guidelines for the diagnosis and management of pericardial diseases: the task force for the diagnosis and management of pericardial diseases of the European Society of Cardiology (ESC)Endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36(42):2921–2964.
   PubMed Web of Science ®Google Scholar
• Imazio M, Brucato A, Cemin R, et al. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2013;369(16):1522–1528.
   PubMed Web of Science ®Google Scholar
• Klein A, Cremer P, Kontzias A, et al. US database study of clinical burden and unmet need in recurrent pericarditis. J Am Heart Assoc. 2021;10(15):e018950.
   PubMed Web of Science ®Google Scholar
• Brucato A, Imazio M, Cremer PC, et al. Recurrent pericarditis: still idiopathic? The pros and cons of a well-honoured term. Intern Emerg Med. 2018;13(6):839–844.
   PubMed Web of Science ®Google Scholar
• Brucato A, Imazio M, Gattorno M, et al., Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical trial. JAMA. 2016;316(18):1906–1912.
   PubMed Web of Science ®Google Scholar
• Klein AL, Lin D, Cremer PC, et al. Efficacy and safety of rilonacept for recurrent pericarditis: results from a phase II clinical trial. Heart. 2020;107(6):488–496.
   Web of Science ®Google Scholar
• Picco P, Brisca G, Traverso F, et al. Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease? Arthritis Rheumatism. 2009;60(1):264–268.
   PubMed Web of Science ®Google Scholar
• Klein AL, Imazio M, Cremer P, et al., Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis. N Engl J Med. 2021;384(1):31–41.
   PubMed Web of Science ®Google Scholar
• Kougkas N, Fanouriakis A, Papalopoulos I, et al. Canakinumab for recurrent rheumatic disease associated-pericarditis: a case series with long-term follow-up. Rheumatology (Oxford). 2018;57(8):1494–1495.
   PubMed Web of Science ®Google Scholar
• Brucato A, Emmi G, Cantarini L, et al. Management of idiopathic recurrent pericarditis in adults and in children: a role for IL-1 receptor antagonism. Intern Emerg Med. 2018;13(4):475–489.
   PubMed Web of Science ®Google Scholar
• Vianello F, Cinetto F, Cavraro M, et al. Azathioprine in isolated recurrent pericarditis: a single centre experience. Int J Cardiol. 2011;147(3):477–478.
   PubMed Web of Science ®Google Scholar
• Imazio M, Lazaros G, Picardi E, et al. Intravenous human immunoglobulins for refractory recurrent pericarditis: a systematic review of all published cases. J Cardiovasc Med (Hagerstown). 2016;17(4):263–269.
   PubMed Web of Science ®Google Scholar
• Lazaros G, Antonopoulos AS, Antonatou K, et al. Hydroxychloroquine for colchicine-resistant glucocorticoid-dependent idiopathic recurrent pericarditis: a pilot observational prospective study. Int J Cardiol. 2020;311:77–82.
   PubMed Web of Science ®Google Scholar
• Klein AL, Imazio M, Brucato A, et al. RHAPSODY: rationale for and design of a pivotal Phase 3 trial to assess efficacy and safety of rilonacept, an interleukin-1alpha and interleukin-1beta trap, in patients with recurrent pericarditis. Am Heart J. 2020;228:81–90.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–1131.
   PubMed Web of Science ®Google Scholar
• Gaspari S, Marsili M, Imazio M, et al. New insights in the pathogenesis and therapy of idiopathic recurrent pericarditis in children. Clin Exp Rheumatol. 2013;31(5):788–794.
   PubMed Web of Science ®Google Scholar
• Cremer PC, Kumar A, Kontzias A, et al. Complicated pericarditis: understanding risk factors and pathophysiology to inform imaging and treatment. J Am Coll Cardiol. 2016;68(21):2311–2328.
   PubMed Web of Science ®Google Scholar
• Maestroni S, Di Corato PR, Cumetti D, et al. Recurrent pericarditis: autoimmune or autoinflammatory? Autoimmun Rev. 2012;12(1):60–65.
   PubMed Web of Science ®Google Scholar
• Sfriso P, Ghirardello A, Botsios C, et al. Infections and autoimmunity: the multifaceted relationship. J Leukoc Biol. 2010;87(3):385–395.
   PubMed Web of Science ®Google Scholar
• Cusick MF, Libbey JE, Fujinami RS. Molecular mimicry as a mechanism of autoimmune disease. Clin Rev Allergy Immunol. 2012;42(1):102–111.
   PubMed Web of Science ®Google Scholar
• Imazio M, Brucato A, Doria A, et al. Antinuclear antibodies in recurrent idiopathic pericarditis: prevalence and clinical significance. Int J Cardiol. 2009;136(3):289–293.
   PubMed Web of Science ®Google Scholar
• Caforio AL, Brucato A, Doria A, et al. Anti-heart and anti-intercalated disk autoantibodies: evidence for autoimmunity in idiopathic recurrent acute pericarditis. Heart. 2010;96(10):779–784.
   PubMed Web of Science ®Google Scholar
• Cantarini L, Lucherini OM, Cimaz R, et al. Idiopathic recurrent pericarditis refractory to colchicine treatment can reveal tumor necrosis factor receptor-associated periodic syndrome. Int J Immunopathol Pharmacol. 2009;22(4):1051–1058.
   PubMed Web of Science ®Google Scholar
• Abbate A, Toldo S, Marchetti C, et al. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease. Circ Res. 2020;126(9):1260–1280.
   PubMed Web of Science ®Google Scholar
• Buckley LF, Viscusi MM, Van Tassell BW, et al. Interleukin-1 blockade for the treatment of pericarditis. Eur Heart J Cardiovasc Pharmacother. 2018;4(1):46–53.
   PubMed Web of Science ®Google Scholar
• Imazio M, Lazaros G, Brucato A, et al. Recurrent pericarditis: new and emerging therapeutic options. Nat Rev Cardiol. 2016;13(2):99–105.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Dinarello CA, Molgora M, et al. Interleukin-1 and related cytokines in the regulation of inflammation and immunity. Immunity. 2019;50(4):778–795.
   PubMed Web of Science ®Google Scholar
• Imazio M, Lazaros G, and Gattorno M, et al. Anti-interleukin-1 agents for pericarditis: a primer for cardiologists. Eur Heart J. 2021 Sep 16 :ehab4 DOI:https://doi.org/10.1093/eurheartj/ehab452. Epub ahead of print. PMID: 34528670.
   Google Scholar
• Cavalli G, Colafrancesco S, Emmi G, et al. Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases. Autoimmun Rev. 2021;20(3):102763.
   PubMed Web of Science ®Google Scholar
• Yu JW, Wu J, Zhang Z, et al. Cryopyrin and pyrin activate caspase-1, but not NF-κB, via ASC oligomerization. Cell Death Differ. 2006;13(2):236–249.
   PubMed Web of Science ®Google Scholar
• Nambayan RJT, Sandin SI, Quint DA, et al. The inflammasome adapter ASC assembles into filaments with integral participation of its two Death Domains, PYD and CARD. J Biol Chem. 2019;294(2):439–452.
   PubMed Web of Science ®Google Scholar
• Mauro AG, Bonaventura A, Vecchié A, et al., The role of NLRP3 inflammasome in pericarditis: potential for therapeutic approaches. JACC Basic Transl Sci. 2021;6(2):137–150.
   PubMedGoogle Scholar
• Petrilli V, Dostert C, Muruve DA, et al. The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol. 2007;19(6):615–622.
   PubMed Web of Science ®Google Scholar
• March CJMB, Larsen A, Cerretti DP, et al. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature. 1985;315(6021):641–647.
   PubMed Web of Science ®Google Scholar
• Gery IGR, Waksman BH, Waksman BH. Potentiation of the T-lymphocyte response to mitogens. I. The responding cell. J Exp Med. 1972;136(1):128–142. PMID: 5033417; PMCID: PMC2139184.
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11(8):633–652.
   PubMed Web of Science ®Google Scholar
• Imazio M, Andreis A, De Ferrari GM, et al. Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: the IRAP (International Registry of Anakinra for Pericarditis) study. Eur J Prev Cardiol. 2020;27(9):956–964.
   PubMed Web of Science ®Google Scholar
• Lazaros G, Antonatou K, Vassilopoulos D. The therapeutic role of Interleukin-1 inhibition in idiopathic recurrent pericarditis: current evidence and future challenges. Front Med (Lausanne). 2017;4:78.
   PubMed Web of Science ®Google Scholar
• Epçaçan S, Sahin S, Kasapcopur O. Anaphylactic reaction to anakinra in a child with steroid-dependent idiopathic recurrent pericarditis and successful management with canakinumab. Cardiol Young. 2019;29(4):549–551.
   PubMed Web of Science ®Google Scholar
• Van Tassell BW, Toldo S, Mezzaroma E, et al. Targeting interleukin-1 in heart disease. Circulation. 2013;128(17):1910–1923.
   PubMed Web of Science ®Google Scholar
• Klein AL, Lin D, Cremer PC, et al. Efficacy and safety of rilonacept for recurrent pericarditis: results from a phase II clinical trial. Heart. 2021;107(6):488.
   Web of Science ®Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT04687358
   Google Scholar
• Regeneron Pharmaceuticals Inc. Arcalyst® [package insert]. Tarrytown NY: USA. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/125249s000TOC.cfm
   Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT03980522
   Google Scholar
• Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheumatism. 2008;58(8):2443–2452.
   PubMed Web of Science ®Google Scholar
• Imazio M, Brucato A, Lazaros G, et al. Anti-inflammatory therapies for pericardial diseases in the COVID-19 pandemic: safety and potentiality. J Cardiovasc Med. 2020;21(9):9.
   Google Scholar
• Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2(6):e325–e31.
   PubMedGoogle Scholar